Efficacy and Safety of Tanz ânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Conditions:   Erectile Dysfunction;   Benign Prostatic Hyperplasia Interventions:   Drug: Tanzânia association;   Drug: Omnic Ocas Sponsor:   EMS Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 26 December 2019Source: Neurobiology of StressAuthor(s): Silvia Diviccaro, Roberto Cosimo Melcangi, Silvia GiattiAbstractThe presence of side effects during pharmacological treatment is unfortunately a quite common problem. In this review, we focused our attention on adverse events related to 5 alpha-reductase (5α-R) inhibitors (i.e., finasteride and dutasteride), approved for the treatment of benign prostatic hyperplasia and androgenetic alopecia (AGA).Although these drugs are generally well tolerated, many reports described adverse effects in men during treatment, such as sexual d...
Source: Neurobiology of Stress - Category: Neuroscience Source Type: research
Conditions:   Erectile Dysfunction;   Benign Prostatic Hyperplasia Interventions:   Drug: Tanzânia association;   Drug: Omnic Ocas;   Other: Omnic Ocas placebo;   Other: Tanzânia association placebo Sponsor:   EMS Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery.Materials and methodsBy immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples.ResultsOur results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, ...
Source: Andrology - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Condition is risk factor for benign prostatic hyperplasia, cardiovascular disease, dementia
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Internal Medicine, Neurology, Oncology, Urology, Journal, Source Type: news
Abstract Erectile dysfunction (ED) is a common male sexual dysfunction associated with a reduced quality of life for patients and their partners. ED is associated with increasing age, depression, obesity, lack of exercise, diabetes mellitus, hypertension, dyslipidaemia, cardiovascular disease and lower urinary tract symptoms related to benign prostatic hyperplasia. The evaluation of men with ED requires a full medical and personally and culturally sensitive sexual history, a focused clinical examination, fasting glucose levels, a fasting lipid profile and, in select cases, a total testosterone level and a prostate...
Source: Med J Aust - Category: General Medicine Authors: Tags: Med J Aust Source Type: research
Conclusions Aging leads to a progressive decrease in androgen production that, in turn, leads to the development of LOH, defined by significant low T serum levels (in the lowest quartile) in the presence of signs and symptoms of hypogonadism (51). LOH could be due to both testicular and hypothalamic-pituitary dysfunction (32), and ED is one of its main symptoms. ED in LOH is linked to increased oxidative stress, subclinical inflammation, and subsequent endothelial dysfunction (101). In elderly men, it has been shown that LOH is also linked to lower cAMP pool and to an alteration of the cGMP signaling pathway. PDE5 gene l...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conclusion: The present study has demonstrated satisfactory good efficacy and safety of PKVP on the long term.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
Conclusion: TUNA can be considered as a relatively effective technique with a good safety profile. The current study demonstrated both significant subjective and objective improvements over 10 and 8 years of follow-up, respectively. It can be considered as a preferable option for patients who prefer surgical option with preservation of their sexual function and fertility.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) - PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED). Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and pr...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Boston Scientific revealed promising 4-year-data from a post-market clinical trial evaluating the Rezūm Water Vapor Therapy in the treatment of benign prostatic hyperplasia (BPH). Results from the Marlborough, MA-based company’s trial show the device provides sexual function four years after the treatment. The clinical trial results showed a surgical retreatment rate of 4.4% and no new adverse events noted between years three and four. The clinical results also highlighted continued preservation of sexual function, including no de novo erectile dysfunction reported at four years. The results ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
More News: Benign Prostatic Hyperplasia | Erectile Dysfunction | Research